Published in Biotech Business Week, April 16th, 2007
This round was led by a global syndicate of new investors from both US and Europe including BioMedInvest, OrbiMed Advisors, LLC and Life Sciences Partners (LSP) as well as the existing investor firstVentury.
Based on its proprietary TandAb(TM) tetravalent antibody format the Company will focus on their two clinical lead programs, a TandAb for the treatment of Hodgkin's disease and another for the treatment of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.